Xeris Biopharma Holdings Inc reports results for the quarter ended December 31 - Earnings Summary

• Xeris Biopharma Holdings Inc XERS.OQ reported a quarterly adjusted loss of 3 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -10 cents. The mean expectation of six analysts for the quarter was for a loss of 6 cents per share. Wall Street expected results to range from -10 cents to -2 cents per share.

• Revenue rose 35.4% to $60.10 million from a year ago; analysts expected $58.10 million.

• Xeris Biopharma Holdings Inc's reported EPS for the quarter was a loss of 3 cents​.

• The company reported a quarterly loss of $5.11 million.

• Xeris Biopharma Holdings Inc shares had risen by 11.2% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 17.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Xeris Biopharma Holdings Inc is $5.00

This summary was machine generated from LSEG data March 6 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)